|Monday October 22, 7:32 am Eastern Time|
SOURCE: Neurocrine Biosciences, Inc.
Neurocrine Biosciences Announces Appointment of Executive Vice President of Clinical Development
SAN DIEGO, Oct. 22 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX - news) announced today the appointment of Henry Y. Pan, M.D., Ph.D., F.A.C.C. to the position of Executive Vice President of Clinical Development and Chief Medical Officer. Dr. Pan has gained worldwide recognition as a senior executive with major pharmaceutical, healthcare, and technology companies. He brings to Neurocrine over 20 years of experience in the pharmacological, medical, clinical pharmacological, and drug development.
Dr. Pan joins Neurocrine from VennWorks LLC, an operating company that creates, builds, and operates high value companies in different technology areas. At VennWorks, he was a Managing Director of the operating company, and CEO of VennWorks RTP, an incubator company that focused in Life Sciences. Prior to joining VennWorks, Dr. Pan was the President, CEO and Managing Partner of Pharmacologics LLC, and was President & CEO of the Pharmaceutical Services division of MDS Inc., a fully integrated Contract Research Organization that included MDS Harris, MDS Panlabs, MDS Clinical Trial Laboratories, among others. Dr. Pan also served as Executive Vice President, Drug Development and Medical Affairs with DuPont Merck Pharmaceutical Company, now a Bristol-Myers Squibb Company. There, he was responsible for the success of the Coumadin, Cardiolite, Neurolite, ReVia, and Sustiva programs. In addition to his tenure at DuPont Merck, Dr. Pan was Vice President of Clinical Research and Development at Bristol-Myers Squibb where he was instrumental in the development of Pravachol taking the compound from preclinical development to drug approval and launch in over 90 countries around the world. Dr. Pan was also directly involved with numerous FDA Advisory Committee meetings at both Bristol-Myers Squibb and DuPont Merck and he was the recipient of numerous company and state awards.
Dr. Pan is a Fellow of the American College of Clinical Cardiology, the American College of Clinical Pharmacology, the American Heart Association, the Institute of Biological and Clinical Investigation, and the Academy of Medicine of New Jersey.
``We are pleased to have Dr. Pan as a member of our senior management team at Neurocrine. His vast knowledge and expertise in both the clinical and scientific arena will significantly accelerate Neurocrine's development and commercialization efforts. With six products in advanced clinical development, it is an asset to have Dr. Pan join Neurocrine at this time of major progress,'' said Gary Lyons, President and Chief Executive Officer of Neurocrine Biosciences.
Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, malignant brain tumors and peripheral cancers, diabetes, multiple sclerosis, irritable bowel syndrome, eating disorders, pain, stroke, and certain female health disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the Internet at neurocrine.com .
In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward looking statements are risks and uncertainties associated with Neurocrine's development programs and business and finances including, but not limited to, risk that Neurocrine's development programs will not successfully proceed through Phase I clinical trials or that in later stage clinical trials will not show that it is effective in treating humans; determinations by regulatory and governmental authorities; uncertainties relating to patent protection and intellectual property rights of third parties; impact of competitive products and technological changes; availability of capital and cost of capital; and other material risks. A more complete description of these risks can be found in the Company's Form 10K for the year ended December 31, 2000 and the current form 10Q each of which should be read before making any investment in Neurocrine common stock. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.
SOURCE: Neurocrine Biosciences, Inc.